Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 7/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.40 |
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | RAF1 | P04049 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | CDC25B | P30305 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 2/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mitoquidone SCHEMBL21570575 | 0.92 | MAPT (0.38) | MAOAMAPTKMT2AEGFRMAPK1 | |
| SCHEMBL10376448 | 0.86 | MAOA (0.50) | MAOAMAPTKMT2AMAPK1LMNA | |
| SCHEMBL10376475 | 0.85 | MAPT (0.45) | MAOAMAPTKMT2AEGFRMAPK1 | |
| SCHEMBL10376512 | 0.85 | ALDH1A1 (0.51) | MAOAMAPTKMT2AMAPK1LMNA | |
| SCHEMBL10376125 | 0.83 | MAPT (0.46) | MAPTKMT2AEGFRMAPK1LMNA | |
| SCHEMBL10376490 | 0.82 | ACHE (0.32) | MAOACES1BCHECYP1A2 | |
| SCHEMBL10376478 | 0.73 | MAPT (0.39) | MAOAMAPTKMT2AEGFRMAPK1 | |
| SCHEMBL10378104 | 0.71 | MAOA (0.38) | MAOAMAPTKMT2AEGFRMAPK1 | |
| SCHEMBL10376481 | 0.71 | ALOX15 (0.48) | MAOAMAPTKMT2AEGFRMAPK1 | |
| SCHEMBL10378389 | 0.69 | ALDH1A1 (0.38) | MAOAMAPTKMT2AMAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 651 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| JP-2011528275-A | — | — | 2011-11-17 | — | — | JP | claimed |
| EP-2313122-A1 | DRUG DELIVERY MEDICAL DEVICE | Micell Technologies, Inc. (US) | 2011-04-27 | — | — | EP | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| WO-2010009335-A1 | DRUG DELIVERY MEDICAL DEVICE | MICELL TECHNOLOGIES, INC. (US) | 2010-01-21 | — | — | WO | claimed |
| US-20090054369-A1 | PHARMACEUTICAL COMPOSITIONS OF SILICON-CONTAINING SUBSTITUTED ADENOSINE NUCLEOSIDE AMIDE ANALOGS | RND PHARMACEUTICALS, INC. (US) | 2009-02-26 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| EP-1919929-A4 | PHARMACEUTICAL COMPOSITIONS OF SILICON-CONTAINING SUBSTITUTED ADENOSINE NUCLEOSIDE AMIDE ANALOGS | RND PHARMACEUTICALS INC (US) | 2008-08-06 | — | — | EP | claimed |
| EP-1919929-A2 | PHARMACEUTICAL COMPOSITIONS OF SILICON-CONTAINING SUBSTITUTED ADENOSINE NUCLEOSIDE AMIDE ANALOGS | RND Pharmaceuticals, Inc. (US) | 2008-05-14 | — | — | EP | claimed |
| CN-1846670-A | Anticancer implant | JINAN SHUAIHUA MEDICINE SCI TE (CN) | 2006-10-18 | — | — | CN | claimed |
| CN-1846689-A | Slow-released anticancer prepn containing taxane and its synergist | JINAN KANGQUAN MEDICINE SCI TE (CN) | 2006-10-18 | — | — | CN | claimed |
| CN-1839843-A | Fluorouracil slow release injection | JINAN SHUAIHUA MEDICINE TECHNO (CN) | 2006-10-04 | — | — | CN | claimed |
| CN-1824314-A | Slow-release agent containing hormone anticancer medicine | JINAN KANGQUAN MEDICINE SCI & (CN) | 2006-08-30 | — | — | CN | claimed |
| CN-1748671-A | Slow releasing injection containing anti-mitosis medicine | KONG QINGZHONG (CN) | 2006-03-22 | — | — | CN | claimed |
| CN-1733301-A | Anticancer implantation agent | KONG QINGZHONG (CN) | 2006-02-15 | — | — | CN | claimed |
| CN-1679950-A | Anticarcinogenic internal implant agent | LANJIN BIOLOG ENGINEERING CO L (CN) | 2005-10-12 | — | — | CN | claimed |
| CN-1660436-A | Anticancer combination of medication | LANJIN BIOLOG ENGINEERING CO L (CN) | 2005-08-31 | — | — | CN | claimed |
| EP-0393575-B1 | Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent | SEARLE & CO (US) | 1994-03-16 | — | — | EP | claimed |
| EP-0393575-A1 | Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent | G.D. Searle & Co. (US) | 1990-10-24 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054369-A1 | PHARMACEUTICAL COMPOSITIONS OF SILICON-CONTAINING SUBSTITUTED ADENOSINE NUCLEOSIDE AMIDE ANALOGS | SI, SLC29A2, SLC29A1 | MAOA 2229/4885MAPT 2400/4885KMT2A 2193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.